Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of two zoledronic acid dosing regimens in pediatric osteogenesis imperfecta (extension of CZOL446H2202)
2004-001666-40Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in osteogenesis imperfecta (OI) (2 arms), sponsored by Novartis. Primary endpoint: Bone mineral density at lumbar spine and total body. Started Nov 2004; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2004-001666-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001666-40.